Study 1 of 24 for search of: defend
Previous Study Return to Search Results Next Study

Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase 3 Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
This study is ongoing, but not recruiting participants.
First Received: May 13, 2008   Last Updated: December 17, 2009   History of Changes
Sponsor: Tolerx Inc.
Collaborator: Juvenile Diabetes Research Foundation
Information provided by: Tolerx Inc.
ClinicalTrials.gov Identifier: NCT00678886
  Purpose

To find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo. Insulin secretion will be assessed using mixed meal-stimulated C-peptide.

Subjects will be assigned to receive either otelixizumab or placebo at a ratio of 2:1 (2/3 otelixizumab, 1/3 placebo). These study agents will be administered as an addition to insulin, diet, and other standard of care treatments.

DEFEND-1 is now closed to enrollment.

DEFEND-2 will begin early in 2010. It is very similar to DEFEND-1 and will again require subjects with new onset type 1 diabetes. Please check back here for more details.

In the meantime, established and new onset type 1 diabetes patients in North America are welcome to consider the TTEDD study:

http://www.clinicaltrials.gov/ct2/show/NCT00451321?term=TTEDD&rank=1


Condition Intervention Phase
Type 1 Diabetes Mellitus
Biological: otelixizumab
Biological: placebo
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND

Resource links provided by NLM:


Further study details as provided by Tolerx Inc.:

Primary Outcome Measures:
  • Amount of C-peptide (a protein that shows how much insulin the body is producing) during a mixed meal stimulation test. [ Time Frame: at 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Average daily insulin use, HbA1c (a measurement of blood glucose control), and incidence of abnormal blood glucose levels. [ Time Frame: at Months 6, 12, 18, and 24 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 240
Study Start Date: May 2008
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
otelixizumab
Biological: otelixizumab
infusion
2: Placebo Comparator Biological: placebo
infusion

Detailed Description:

The following visits are required:

  • Screening Visits: 2 to 3 appointments will be conducted to determine eligibility. At 2 of these visits participants will drink a liquid meal and have blood tests done over the post-meal period.
  • Dosing Visits: 8 outpatient visits on consecutive days, each lasting about 4-6 hours.
  • Follow-up Visits: weekly for the first month, then every 2 weeks for 3 months, followed by monthly visits through 1 year. There will be 3 visits in the second year.
  • The total duration of the study is 2 years.
  • Glucose test strips, glucose monitors and PDAs to record insulin will be provided to all study subjects for the duration fo the study. Frequent glycemic monitoring will occur through lab testing and blood glucose self-monitoring to help facilitate tight glycemic control in all subjects.
  Eligibility

Ages Eligible for Study:   12 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ages 12-45
  • Diagnosis of diabetes mellitus, consistent with ADA criteria
  • No more than 90 days between diagnosis and administration of study compounds
  • Requires insulin for Type I Diabetes Mellitus, or has required insulin at some time between diagnosis and administration of study compounds.
  • Stimulated C-peptide level greater than 0.20 nmol/L and less than or equal to 3.50 nmol/L
  • Positive for one or more of the autoantibodies typically associated with T1DM: antibody to glutamic acid decarboxylase (anti‑GAD); antibody to protein tyrosine phosphatase-like protein (anti‑IA‑2); zinc transporter autoantibodies (ZNT8); insulin autoantibodies (IAA). A subject who is positive for insulin autoantibodies (IAA) and negative for the other autoantibodies will only be eligible if the subject has used insulin for less than 7 days total.

Exclusion Criteria:

  • Other, significant medical conditions based on the study doctor's evaluation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00678886

  Hide Study Locations
Locations
United States, Alabama
Univ. of Alabama at Birmingham School of Medicine (recruiting ages 12-45)
Birmingham, Alabama, United States, 35294
United States, Arkansas
Little Rock Diagnostic Clinic (recruiting ages 18-45)
Little Rock, Arkansas, United States, 72205
United States, California
Diablo Clinical Research (recruiting ages 12-45)
Walnut Creek, California, United States, 94598
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (recruiting ages 12-45)
Torrance, California, United States, 90502
Clinical Innovations, Inc. (recruiting ages 12-45)
Riverside, California, United States, 92506
Clinical Innovations, Inc. (recruiting ages 18-45)
Santa Ana, California, United States, 92705
Clinical Innovations, Inc. (recruiting ages 18-45)
Costa Mesa, California, United States, 92626
St. Joseph Hospital (recruiting ages 18-45)
Orange, California, United States, 92868
Children's Hospital of Orange County (recruiting 12-17)
Orange, California, United States, 92868
SunRise Clinical Research
Bell Gardens, California, United States, 90201
United States, Colorado
Barbara Davis Center for Childhood Diabetes/ University of Colorado Health Sciences Center (recruiting ages 12-45)
Aurora, Colorado, United States, 80015
United States, District of Columbia
George Washington University (recruiting ages 12-45)
Washington, D.c., District of Columbia, United States, 20037
United States, Florida
Elite Research Institute (recruiting ages 18-45)
Miami, Florida, United States, 33169
Advanced Diabetes Treatment Centers/ Clinical Trials Management, LLC (recruiting ages 12-45)
Orlando, Florida, United States, 32803
Advanced Diabetes Treatment Centers/ Clinical Trials Management, LLC (recruiting ages 18-45)
Boca Raton, Florida, United States, 33486
Orlando Diabetes and Endocrine Specialists (recruiting ages 17-45)
Orlando, Florida, United States, 32835
Advanced Research Institute, Inc. (recruiting ages 18-45)
Trinity, Florida, United States, 34655
Advanced Pharma Clinical Research
Miami, Florida, United States, 33142
United States, Georgia
Laureate Clinical Medical Research (recruiting ages 12-45)
Atlanta, Georgia, United States, 30342
Atlanta Diabetes Associates (recruiting ages 12-45)
Atlanta, Georgia, United States, 30309
United States, Hawaii
Hawaii Clinical Research Center (recruiting ages 18-45)
Honolulu, Hawaii, United States, 96813
United States, Idaho
Rocky Mountrain Diabetes and Osteoporosis Center (recruiting ages 12-45)
Idaho Falls, Idaho, United States, 83404
Humphrey Diabetes Center (recruiting ages 12-45)
Boise, Idaho, United States, 83702
United States, Illinois
University of Chicago (recruiting ages 12-45)
Chicago, Illinois, United States, 60637
John H. Stroger Jr. Hospital of Cook Country (recruiting ages 18-45)
Chicago, Illinois, United States, 60612
United States, Kansas
Cotton-O'Neil Diabetes and Endocrinology Center (recruiting ages 12-45)
Topeka, Kansas, United States, 66606
United States, Maryland
University of Maryland School of Medicine/Joslin Diabetes Center (recruiting ages 12-45)
Baltimore, Maryland, United States, 21201
United States, Massachusetts
University of Massachusetts, Memorial Hospital (recruiting ages 12-45)
Worcester, Massachusetts, United States, 01655
United States, Michigan
Borgess Research Institute (recruiting ages 12-45)
Kalamazoo, Michigan, United States, 49048
United States, Mississippi
Gulfside Clinical Research, LLC (recruiting ages 12-45)
Gulfport, Mississippi, United States, 39501
United States, Missouri
Washington University School of Medicine (recruiting ages 16-45)
St. Louis, Missouri, United States, 63110
University of Missouri (recruiting ages 12-45)
Columbia, Missouri, United States, 65212
Kansas City University of Medicine and Biosciences (recruiting ages 18-45)
Kansas City, Missouri, United States, 64106
United States, Nebraska
Creighton University Medical Center (recruiting ages 12-45)
Omaha, Nebraska, United States, 68131
United States, New Jersey
Meridian Medical Associates (recruiting ages 12-45)
Neptune, New Jersey, United States, 07753
United States, New York
The University of Rochester Medical Center (recruiting ages 18-45)
Rochester, New York, United States, 14627
State University of New York at Buffalo and Kaleida Health/Diabetes Center of WNY (recruiting ages 18-45)
Buffalo, New York, United States, 14209
Winthrop University Hospital (recruiting ages 18-45)
Mineola, New York, United States, 11501
Columbia University Medical Center/ Naomi Berrie Diabetes Center (recruiting ages 12-45)
New York, New York, United States, 10032
United States, North Carolina
University of North Carolina Diabetes Center (recruiting ages 18-45)
Durham, North Carolina, United States, 27713
United States, Ohio
Dayton Science Institute, LLC (recruiting ages 12-45)
Dayton, Ohio, United States, 45419
Your Diabetes Endocrine Nutrition Group, LLC/ Clinical Research Department (recruiting ages 12-45)
Mentor, Ohio, United States, 44060
The Ohio State University (recruiting ages 12-45)
Columbus, Ohio, United States, 43201
Nationwide Childresn's Hospital
Columbus, Ohio, United States, 43205
United States, Oklahoma
Vital Prospects Clinical Research Institute, PC (recruiting ages 14-45)
Tulsa, Oklahoma, United States, 74136
United States, Oregon
Clinical Trials of America, Inc. (recruiting ages 12-45)
Eugene, Oregon, United States, 97401
Portland Diabetes & Endocrinology Center P.C. (Recruting ages 18-45)
Portland, Oregon, United States, 97210
United States, Pennsylvania
St. Mary Medical Center (recruiting ages 18-45)
Langhorne, Pennsylvania, United States, 19047
Temple University Hospital (recruiting ages 18-45)
Philadelphia, Pennsylvania, United States, 19140
United States, South Carolina
Medical University of South Carolina (recruiting ages 18-45)
Charleston, South Carolina, United States, 29425
United States, South Dakota
Dakota Regional Medical Clinic (recruiting ages 12-45)
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Ramesh C. Gupta, MD (recruiting ages 16-45)
Memphis, Tennessee, United States, 38119
University Diabetes and Endocrine Consultants (recruiting ages 12-45)
Chattanooga, Tennessee, United States, 37403
Vanderbilt Diabetes Research and Training Center (recruiting ages 18-45)
Nashville, Tennessee, United States, 37212
United States, Texas
Diabetes and Glandular Disease Clinic (recruiting ages 12 - 45)
San Antonio, Texas, United States, 78229
InVision Consultants, LLC (recruiting ages 12-45)
San Antonio, Texas, United States, 78217
Potenium Clinical Research (recruiting ages 15-45)
Hurst, Texas, United States, 76304
Baylor College of Medicine (recruiting ages 12-45)
Houston, Texas, United States, 77030
UT Southwestern Medical Center - Dallas (recruiting ages 14-45)
Dallas, Texas, United States, 75390-8858
Research Institute of Dallas (recruiting ages 12-45)
Dallas, Texas, United States, 75231
United States, Utah
Endocrine Research Specialists (recruiting ages 12-45)
Ogden, Utah, United States, 84403
United States, Washington
Liberty Research Center (recruiting ages 12-45)
Tacoma, Washington, United States, 98405
Canada, Ontario
LMC Endocrinology Centres Ltd. (recruiting ages 18-45)
Toronto, Ontario, Canada, M4R 2G4
LMC Endocrinology Centres Ltd. (recruiting ages 18-45)
Oakville, Ontario, Canada, L6H 3P1
Canadian Centre for Research on Diabetes (recruiting ages 18-45)
Smith Falls, Ontario, Canada, K7A4W8
Canada, Quebec
Dynamik Research, Inc (recruiting ages 18-45)
Pointe-Claire, Quebec, Canada, H9R 3J1
Denmark
Århus Sygehus (recruiting ages 18-35)
Århus C, Denmark, 8000
Hospital of Soutwest Denmark (recruiting ages 18-35)
Esbjerg, Denmark, 6700
Finland
ODL Terveys OY (recruiting ages 18-35)
Oulu, Finland, 90100
Tampereen Yliopistollinen Sairaala (recruiting ages 18-35)
Tampere, Finland, 33520
Satakunnan Keskussairaala (recruiting ages 18-35)
Pori, Finland, 28500
Kuopion Yliopistollinen Sairaala (recruiting ages 18-35)
Kuopio, Finland, 70210
Turku University Hospital (recruiting ages 18-35)
Turku, Finland, 20502
Åland Central Hospital (recruiting ages 18-35)
Mariehamn, Finland, 22111
Germany
Universitätsklinikum Dresden (recruiting ages 18-35)
Dresden, Germany, 01307
Universitätsklinikum Heidelberg (recruiting ages 18-35)
Heidelberg, Germany, 69120
Diabeteszentrum Bad Lauterberg (recruiting ages 18-35)
Bad Lauterberg, Germany, 37431
Charite Klinikum Benjamin Franklin (recruiting ages 18-35)
Berlin, Germany, 12200
Diabetes-Klinik Bad Nauheim GmbH (recruiting ages 18-35)
Bad Nauheim, Germany, 61231
Klinikum Innenstadt der Ludwig-Maximilians-Universität München Studienambulanz (recruiting ages 18-35)
München, Germany, 80336
Deutsches Diabetes Zentrum (recruiting ages 18-35)
Düsseldorf, Germany, 40225
Italy
Università Cattolica del Sacro Cuore (recruiting ages 18-35)
Roma, Italy, 00168
Instituto Scientifico San Raffaele (recruiting ages 18-35)
Milano, Italy, 20132
Ospedale S. Maria Goretti Polo Pontino dell'Università La Sapienza di Roma (recruiting ages 18-35)
Latina, Italy, 04100
Università Campus Bio-Medico di Roma (recruiting ages 12-45)
Rome, Italy, 00128
Policlinico P. Giaccone (recruiting ages 18-35)
Palermo, Italy, 90127
Università La Sapienza di Roma (recruiting ages 18-35)
Roma, Italy, 00198
Ospedale Sandro Pertini (recruiting ages 18-35)
Rome, Italy, 00157
Italy, Sardinia
Universitaria di Cagliari Polo Monserrato (recruiting ages 18-35)
Monserrato (Cagliari), Sardinia, Italy, 09042
Spain
Hospital Clínico San Carlos (recruiting ages 18-35)
Madrid, Spain, 28040
Hospital Vall Hebrón (recruiting ages 18-35)
Barcelona, Spain, 08035
Hospital Dr. Peset (recruiting ages 18-35)
Valencia, Spain, 46017
Complejo Hospitalario de Pontevedra Hospital de Montecelo (recruiting ages 18-35)
Pontevedra, Spain, 36071
Hospital Universitario Puerta de Hierro (recruiting ages 18-35)
Madrid, Spain, 28220
Hospital Dr. Josep Trueta (recruiting ages 18-35)
Girona, Spain, 17007
Hospital Mutua de Terrassa (recruiting ages 18-35)
Terrassa, Spain, 08221
Fundación Jiménez-Díaz (recruiting ages 18-35)
Madrid, Spain, 28040
Hospital Son Llatzer (recruiting ages 18-35)
Palma de Mallorca, Spain, 07198
Hospital Universitario Sant Joan (recruiting ages 18-35)
Sant Joan Alicante, Spain, 03550
Sweden
Karolinska Universitetssjukhuset (recruiting ages 18-45)
Stockholm, Sweden, 171 76
Forskningsenheten, Centralsjukhuset I Kristianstad (recruiting ages 18-45)
Kristianstad, Sweden, 291 85
Norrlands Universitetssjukhus (recruiting ages 18-45)
Umea, Sweden, 901 85
Länssjukhuset Halmstad (recruiting ages 18-45)
Halmstad, Sweden, 301 85
Blekingesjukhuset (recruiting ages 18-45)
Karlskrona, Sweden, 371 85
Kärnsjukhuset i Skövde (recruiting ages 18-45)
Skövde, Sweden, 541 85
Centrallasarettet Medicin och Endokrinologmottagningen (recruiting ages 18-45)
Växjö, Sweden, 351 85
Alingsås Lasarett Diabetesmottagningen (recruiting ages 18-45)
Alingsås, Sweden, 441 83
Centralsjuhuset Karlstad (recruiting ages 18-45)
Karlstad, Sweden, 651 85
Oskarshamns Sjukhus Metabolenheten (recruiting ages 18-45)
Oskarshamn, Sweden, 572 28
Köpings Lasarett (recruiting ages 18-45)
Köping, Sweden, 731 81
NSV Lasarettet Motala (recruiting ages 18-45)
Motala, Sweden, 591 85
Härnösands Sjukhus Öbackakliniken (recruiting ages 18-45)
Harnosand, Sweden, 871 82
Lundberg Laboratorium for Diabetic Research/SU Sahlgrenska Sjukhuset (recruiting ages 18-45)
Gothenburg, Sweden, 413 45
United Kingdom
Bristol Royal Infirmary (recruiting ages 18-35)
Bristol, United Kingdom, BS2 8HW
Royal Blackburn Hospital (recruiting ages 18-35)
Blackburn, United Kingdom, BB2 3HH
Newcastle Clinical Research Facility (recruiting ages 18-35)
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Michael White Diabetes Centre (recruiting ages 18-35)
Hull, United Kingdom, HU3 2RW
Royal United Hospital (recruiting ages 18-35)
Bath, United Kingdom, BA1 3NG
Guy's Hospital (recruiting ages 18-35)
London, United Kingdom, SE1 9RT
Lincoln House, Heart of England NHS Trust, Heartlands Hospital (recruiting ages 18-35)
Birmingham, United Kingdom, B9 5SS
Wolfson Clinic Institute of Metabolic Science Addenbrookes Hospital (recruiting ages 18-35)
Cambridge, United Kingdom, CB2 2QQ
United Kingdom, Scotland
Royal Infirmary of Edinburgh (recruiting ages 18-35)
Edinburgh, Scotland, United Kingdom, EH16 4SA
Raigmore Hospital (recruiting ages 18-35)
Inverness, Scotland, United Kingdom, IV2 3JH
Sponsors and Collaborators
Tolerx Inc.
Juvenile Diabetes Research Foundation
  More Information

Additional Information:
Publications:
Responsible Party: Tolerx, Inc. ( Kathleen Osborn/Clinical Study Manager )
Study ID Numbers: TRX4006
Study First Received: May 13, 2008
Last Updated: December 17, 2009
ClinicalTrials.gov Identifier: NCT00678886     History of Changes
Health Authority: United States: Food and Drug Administration;   Canada: Health Canada;   Denmark: Danish Medicines Agency;   Finland: Finnish Medicines Agency;   Germany: Paul-Ehrlich-Institut;   Italy: Ministry of Health;   Spain: Spanish Medicines and Health product Agency;   Sweden: Medical Products Agency;   United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Tolerx Inc.:
Type 1 diabetes
new onset type 1 diabetes
juvenile diabetes
T1DM
Type l diabetes

Additional relevant MeSH terms:
Antibodies, Monoclonal
Autoimmune Diseases
Metabolic Diseases
Immunologic Factors
Immune System Diseases
Diabetes Mellitus, Type 1
Physiological Effects of Drugs
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2010